Dr. Roubille, et al reply

CAMILLE ROUBILLE, VINCENT RICHER, TARA STARNINO, COLLETTE MCCOURT, ALEXANDRA McFARLANE, PATRICK FLEMING, STEPHANIE SIU, JOHN KRAFT, CHARLES LYNDE, JANET E. POPE, WAYNE GULLIVER, STEPHANIE KEELING, JAN DUTZ, LOUIS BESSETTE, ROBERT BISSONNETTE and BOULOS HARAOUI

J Rheumatol 2016;43;993-994
http://www.jrheum.org/content/43/5/993

1. Sign up for TOCs and other alerts
   http://www.jrheum.org/alerts

2. Information on Subscriptions
   http://jrheum.com/faq

3. Information on permissions/orders of reprints
   http://jrheum.com/reprints_permissions

*The Journal of Rheumatology* is a monthly international serial edited by Earl D. Silverman featuring research articles on clinical subjects from scientists working in rheumatology and related fields.
To the Editor:

We thank Castañeda, et al1 for their comments on our article2. We do support comorbidity management in rheumatoid arthritis (RA), psoriatic arthritis (PsA), and psoriasis (PsO) in daily practice to ensure optimal care and outcomes, and completely agree with the recently published Spanish recommendations3. Given that patients with RA have increased risk of cardiovascular (CV) morbidity and mortality4, CV monitoring appears critical. In the CARMA (CARDiovascular in rHEUMAtology) study, Castañeda, et al5 reported that patients with RA, PsA, and PsO had higher prevalence of CV events while receiving biological therapy despite being in low disease activity for almost half of the patients. Notably, almost half of the patients also received nonsteroidal antiinflammatory drugs and/or glucocorticoids (patients with RA), which may have increased CV risk5. Regardless of the other confounding factors, these data reinforce the importance of CV monitoring and appropriate management in these populations. Moreover, in agreement with Castañeda, et al, we also support depression screening and management, as well as vaccinations7, given the increased risk of infection associated with the use of biologic agents. Although of great importance, oral health and sexual disorders have not been selected by the Delphi voting process and were not addressed in our review because of the decision to limit our review to 8 questions/situations. We agree that they are important issues and deserve special attention and specific evidence-based recommendations.

Finally, we strongly recommend a multidisciplinary and integrated approach to improve RA/PsA/PsO comorbidity management.

As to the issue of depression, we thank Mr. Thombs and Dr. Hudson8 for their comments on our article2. We agree that, unfortunately, research on depression screening and management is lacking. Our article was a comprehensive literature review identifying multiple studies that demonstrated that the prevalence of depression in patients with psoriatic disease and RA was higher compared with control groups9,10,11,12,13,14,15,16,17. A published metaanalysis that helped corroborate our finding reported an overall depression prevalence of 28% in PsO and that patients with PsO were more likely to have depression than those without PsO (OR 1.57, 95% CI 1.40–1.76)18. There appears to be robust data to support the higher risk of depression among our patients with chronic inflammatory disorders.

We do agree that screening for depression in the general population can be quite controversial and recognize that several conflicting sets of guidelines have been published. For example, the US Preventative Services Task Force recommends routine screening of all adults by their primary care provider when appropriate supports are available19. In the past, Canadian guidelines had endorsed a similar recommendation20, although more current analysis did not find sufficient evidence to recommend for or against routine screening in at-risk populations21.

Screening can take many forms such as compressive self-administered questionnaires. However, screening need not be arduous or time-consuming. An alternative screening method can include simple tools such as the “2-question” approach endorsed by the US Preventative Services Task Force: “Over the past 2 weeks, have you felt down, depressed, or hopeless?” and “Over the past 2 weeks, have you felt little interest or pleasure in doing things?”22, which can be quite sensitive in detecting depression.

Positive screens do not necessarily require high consumption of our limited healthcare resources. We envision close collaboration with family physicians and nurse practitioners to ensure that patients at risk of depression have their healthcare needs met. Thombs and Hudson report being concerned that a positive screen test may result in the potentially unnecessary use of antidepressants. However, with such rapid screening questions, we do not expect that antidepressants would be considered until after a clinical assessment of our patients. We also encourage a broad definition of depression management that does not focus solely on the use of antidepressants, but would include supportive counseling, social networks, and peer-support groups.

We hope that future studies will provide a thorough analysis of the harms and benefits of depression screening in patients with PsO, PsA, and RA, and we are actively exploring such research. We also caution about the overvaluation of the randomized controlled trial (RCT) in the assessment of the quality of evidence and invite alternative study designs such as prospective cohorts using methods such as propensity scores and instrumental variables. These may better account for confounding than in the so-called “pragmatic RCT,” which is at risk of postrandomization confounding and selection bias23.

CAMILLE ROUBILLE, MD, Rheumatology Research Fellow, University of Montreal Hospital Research Center (Centre de Recherche du CHUM), Notre-Dame Hospital, Quebec City, Quebec; VINCENT RICHER, MD, Dermatology Resident, Division of Medicine, Dermatology Service, St-Luc Hospital, Quebec City, Quebec; TARA STARNINO, MD, Rheumatology Resident, Sacré-Cœur Hospital of Montreal, University of Montreal, Quebec City, Quebec; COLLETTE MCCOURT, MB, BCH, Clinical Fellow in Immunodermatology, Department of Dermatology and Skin Science, University of British Columbia, Vancouver, British Columbia; ALEXANDRA McFARLANE, MD, Internal Medicine Resident, Division of Rheumatology, University of Alberta, Edmonton, Alberta; PATRICK FLEMING, MD, Dermatology Resident, Division of Dermatology, University of Toronto, Toronto, Ontario; STEPHANIE SIU, MD, Internal Medicine Resident, Division of Rheumatology, Western University of Canada, London, Ontario; JOHN KRAFT, MD, Dermatologist, Lynde Dermatology, Markham, Ontario; CHARLES LYNDE, MD, Dermatologist, Lynde Dermatology, Markham, Ontario; JANET E. POPE, MD, Professor of Rheumatology, Division of Rheumatology, Western University of Canada, London, Ontario; WAYNE GULLIVER, MD, Professor of Medicine, Faculty of Medicine, Memorial University of Newfoundland, St. John’s, Newfoundland; STEPHANIE KEELING, MD, Associate Professor of Rheumatology, Division of Rheumatology, University of Alberta, Edmonton, Alberta; JAN DUTZ, MD, Professor of Dermatology, Department of Dermatology and Skin Science, University of British Columbia, Vancouver, British Columbia; LOUIS BESSETTE, MD, Associate Professor of Medicine, Centre de Recherche du CHU de Québec, Department of Medicine, Laval University, Quebec City, Quebec; ROBERT BISSONNETTE, MD, Medical Director, Innovaderm Research, Quebec City, Quebec; BOULOS HARAOUI, MD, Head of Clinical Research Unit, Institut de Rhumatologie de Montréal, Quebec City, Quebec, Canada. Address correspondence to Dr. C. Roubille, University of Montreal Hospital Research Center (CRCHUM), Notre-Dame Hospital, Montreal, Quebec H2L 1S6, Canada. E-mail: camille.roublle@gmail.com

REFERENCES


